Gait Impairment in Traumatic Brain Injury: A Systematic Review

Dever, Anthony; Powell, Dylan; Graham, Lisa; Mason, Rachel; Das, Julia; Marshall, Steven J.; Vitório, Rodrigo; Godfrey, Alan; Stuart, Samuel

doi:10.3390/s22041480

Cited by 27 publications

(26 citation statements)

References 51 publications

(83 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gait impairment is a classical marker in clinical TBI populations [ 4 , 108 , 109 ]. Gait analysis in animal models of TBI is important because most injury models directly affect the motor circuits that control gait function.…”

Section: Discussionmentioning

confidence: 99%

Activity of a Novel Anti-Inflammatory Agent F-3,6′-dithiopomalidomide as a Treatment for Traumatic Brain Injury

et al. 2022

View full text Add to dashboard Cite

Traumatic brain injury (TBI) is a major risk factor for several neurodegenerative disorders, including Parkinson’s disease (PD) and Alzheimer’s disease (AD). Neuroinflammation is a cause of later secondary cell death following TBI, has the potential to aggravate the initial impact, and provides a therapeutic target, albeit that has failed to translate into clinical trial success. Thalidomide-like compounds have neuroinflammation reduction properties across cellular and animal models of TBI and neurodegenerative disorders. They lower the generation of proinflammatory cytokines, particularly TNF-α which is pivotal in microglial cell activation. Unfortunately, thalidomide-like drugs possess adverse effects in humans before achieving anti-inflammatory drug levels. We developed F-3,6′-dithiopomalidomide (F-3,6′-DP) as a novel thalidomide-like compound to ameliorate inflammation. F-3,6′-DP binds to cereblon but does not efficiently trigger the degradation of the transcription factors (SALL4, Ikaros, and Aiolos) associated with the teratogenic and anti-proliferative responses of thalidomide-like drugs. We utilized a phenotypic drug discovery approach that employed cellular and animal models in the selection and development of F-3,6’-DP. F-3,6′-DP significantly mitigated LPS-induced inflammatory markers in RAW 264.7 cells, and lowered proinflammatory cytokine/chemokine levels in the plasma and brain of rats challenged with systemic LPS. We subsequently examined immunohistochemical, biochemical, and behavioral measures following controlled cortical impact (CCI) in mice, a model of moderate TBI known to induce inflammation. F-3,6′-DP decreased CCI-induced neuroinflammation, neuronal loss, and behavioral deficits when administered after TBI. F-3,6′-DP represents a novel class of thalidomide-like drugs that do not lower classical cereblon-associated transcription factors but retain anti-inflammatory actions and possess efficacy in the treatment of TBI and potentially longer-term neurodegenerative disorders.

show abstract

Section: Discussionmentioning

confidence: 99%

Activity of a Novel Anti-Inflammatory Agent F-3,6′-dithiopomalidomide as a Treatment for Traumatic Brain Injury

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Finally, these results might reflect the characteristics of the specific population, which could have very different mechanisms underlying their impaired gait and motor control. Indeed, in TBI populations a relationship between complexity and walking performance or clinical assessments can also depend on the specific type of brain injury (e.g., a localised lesion within the brain) [ 39 ] or diffuse axonal injury [ 40 ].…”

Section: Discussionmentioning

confidence: 99%

The Effect of Dual-Task Motor-Cognitive Training in Adults with Neurological Diseases Who Are at Risk of Falling

et al. 2022

View full text Add to dashboard Cite

Falls are common in patients with neurological diseases and can be very problematic. Recently, there has been an increase in fall prevention research in people with neurological diseases; however, these studies are usually condition-specific (e.g., only MS, PD or stroke). Here, our aim was to evaluate and compare the efficacy of an advanced and innovative dual-task, motor-cognitive rehabilitation program in individuals with different neurological diseases who are at risk of falling. We recruited 95 consecutive adults with neurological diseases who are at risk of falling and divided them into four groups: 31 with cerebrovascular disease (CVD), 20 with Parkinson’s disease (PD), 23 with traumatic brain injury (TBI) and 21 with other neurological diseases (OND). Each patient completed a dual-task, motor-cognitive training program and underwent two test evaluations to assess balance, gait, fear of falling and walking performance at the pre-and post-intervention. We found that our experimental motor-cognitive, dual-task rehabilitation program was an effective method for improving walking balance, gait, walking endurance and speed, and fear of falling, and that it reduced the risk of falls in patients with different neurological diseases. This study presents an alternative approach for people with chronic neurological diseases and provides innovative data for managing this population.

show abstract

“…Obstacle crossing has been studied in humans with developmental coordination disorder and Parkinson's disease, as well as, children with cerebral palsy stroke, in order to investigate the dynamic balance strategies in these groups and, in some cases, to differentiate people at risk of falls [7]. In humans, walking over obstacles is also a functional test to assess impairment with traumatic brain [8] and spinal cord injury [9].…”

Section: Introductionmentioning

confidence: 99%

Ground Reaction Forces and Center of Pressure within the Paws When Stepping over Obstacles in Dogs

Charalambous

Strasser²,

Tichy³

et al. 2022

Animals

View full text Add to dashboard Cite

Walking over obstacles is a widely used physiotherapy exercise in dogs. Current research is limited to the effect of this exercise in kinematics and muscle activation in dogs. The present study assessed the influence of walking over obstacles on the ground reaction forces (GRFs) and center of pressure (COP) in dogs. Data of dogs walking over one and two obstacles over a pressure platform were retrospectively analyzed and compared to normal walking. Walking over one obstacle did not affect the GRFs and COP of the forelimbs; however, significant changes were observed for the hindlimbs, especially the leading hindlimb. Walking over two obstacles caused significant changes to only one value at the forelimbs, whereas multiple significant changes in the GRFs and COP values were observed at the hindlimbs. Walking over obstacles seems to be challenging even for healthy adult dogs. Further studies are needed to investigate how different heights of obstacles and distances between them can further challenge the animals. The combination of kinetics and kinematics during walking over obstacles may be used in future as a diagnostic tool in geriatric and neurological patients in order to assess their proprioception awareness or to assess the improvement after an intervention, e.g., physiotherapy treatment.

show abstract

Gait Impairment in Traumatic Brain Injury: A Systematic Review

Cited by 27 publications

References 51 publications

Activity of a Novel Anti-Inflammatory Agent F-3,6′-dithiopomalidomide as a Treatment for Traumatic Brain Injury

Activity of a Novel Anti-Inflammatory Agent F-3,6′-dithiopomalidomide as a Treatment for Traumatic Brain Injury

The Effect of Dual-Task Motor-Cognitive Training in Adults with Neurological Diseases Who Are at Risk of Falling

Ground Reaction Forces and Center of Pressure within the Paws When Stepping over Obstacles in Dogs

Contact Info

Product

Resources

About